Controlant's newest location marks another milestone in its mission to unleash zero-waste supply chains and meet the ever-growing demand for its high-tech digital solutions in the global pharmaceutical industry. Presence in Copenhagen positions Controlant to tap into Denmark's strong life-science ecosystem, get closer to its customers, access a large pool of skilled professionals, and more closely collaborate with technology and industry partners.
Gísli Herjólfsson, co-founder and CEO of Controlant attended the opening along with representatives from Invest in Denmark, Copenhagen Capacity, and the Icelandic embassy in Copenhagen, as well customers, partners, investors, members of the board, and employees.
Controlant is on a rapid growth journey driven by increased engagement with the world’s largest pharmaceutical companies and newly established partnerships with leading logistics service providers. With over 430 people from more than 40 different countries, the company has more than doubled in size over the past 18 months. The new office in Copenhagen is the most recent addition to the company’s growing global operations which span offices in Iceland, Poland, the United States, the Netherlands, and now Denmark. Controlant offers its growing global team a supportive, and inclusive working environment, promoting diversity, inclusion, respect, and lifelong learning.
“Controlant is growing fast, and we have ambitious goals to make pharma supply chains around the world agile, resilient, and sustainable so that medicines and vaccines reach the people who need them, with zero-waste. To ensure we are fully prepared for the journey ahead, we are expanding globally, and have established an office in Copenhagen—a strategic location with close proximity to some of the world's leading pharmaceutical companies and logistics providers. Close collaboration with our industry partners will play a critical role in digitizing, automating, and ultimately, transforming global pharma supply chains.”
“We are excited to welcome Controlant to Denmark and to follow their efforts for zero-waste in the pharma supply chain. They are a great addition to our ecosystem and will contribute both to our strong life science cluster as well as the United Nations Sustainable Development Goals and environmental goals we have in Denmark.”
In Denmark, Controlant employs people across various functions with plans for further expansion with a focus on strategic commercial growth.
“We are thrilled to be in the Danish capital, a premier location for high-tech activities. By tapping into Denmark’s strong life-science ecosystem, we can connect with many of our current and future customers in the global pharma industry who have major operations or European headquarters in Copenhagen. We feel welcome in Denmark and look forward to growing our team, bringing on board some of the world-class talent based in Denmark.”
“We are pleased to support Controlant both in establishing activities in Denmark and with their future growth journey. Besides jobs and growth, Controlant brings life-saving innovation to the Danish life science ecosystem and is a prime example of how an ambitious and persistent focus on sustainability and diversity contributes to a successful business. This is a great match with Danish values, and I am convinced Controlant will find like-minded, top-performing talent and benefit from highly competitive Danish framework conditions."
The promise of modern medicine to improve lives and cure more diseases than ever before can only be fulfilled when pharma supply chains provide on-time, safe, and sustainable delivery to patients wherever they may be. Digitalization is the key to unlocking the potential of supply chains to be a strategic enabler in today’s complex and ever-changing market and to achieve zero waste. Controlant’s validated, cloud-based Aurora Platform can be coupled with devices and services for a holistic solution framework designed to digitalize and automate pharma supply chains.
The Science Based Targets initiative (SBTi) has validated Controlant’s near-term climate target to reduce scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030. With a validated target, Controlant becomes one of the first companies among its global industry peers to have a validated science-based target. Joining the initiative is a vital step for Controlant in its mission to deliver zero-waste pharma supply chains and ensure its climate actions are in line with the latest climate science.
UNICEF and Controlant have signed a partnership agreement with a focus on life-saving child immunization. Over the next three years, Controlant will donate to UNICEF yearly for its tireless work that has a direct, positive impact on children across the world.